Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
IPO Year: 2015
Exchange: NASDAQ
Website: benitec.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | $28.00 | Buy | H.C. Wainwright |
| 12/13/2024 | $30.00 | Outperform | Robert W. Baird |
| 10/16/2024 | $35.00 | Outperform | Oppenheimer |
| 9/12/2024 | $17.00 | Buy | Guggenheim |
| 7/22/2024 | $13.00 | Outperform | Leerink Partners |
| 6/13/2024 | $30.00 | Overweight | Piper Sandler |
| 2/17/2022 | $10.00 | Buy | HC Wainwright & Co. |
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13D - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no
-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- -Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below- HAYWARD, Calif., Oct. 12, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform,
3 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
8-K/A - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
SCHEDULE 13G - Benitec Biopharma Inc. (0001808898) (Subject)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
DEFA14A - Benitec Biopharma Inc. (0001808898) (Filer)
10-Q - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences. Piper Sandler Annual Healthcare ConferenceDate: December 4, 2024Time of Fireside Discussion: 12:00 PM ESTLocation: New York, NYFormat: Fireside Discussion & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Oppenheimer Movers in Rare Disease
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. Date: November 11, 2024Time: 2:30 PMFormat: Fireside Chat & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Please contact your Guggenheim representative to schedule a 1x1 me
-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- -Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below- HAYWARD, Calif., Oct. 12, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform,
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July- -Second Subject Dosed with the Low-Dose of BB-301 in February 2024, and Third Subject Expected to Receive the Low-Dose of BB-301 in Calendar Quarter Four of 2024- -Closed an Oversubscribed Private Placement Financing of $40.0 Million on April 22nd, Cash Runway Extended Through 2025- HAYWARD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company dev
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czech Republic from October 8-12, 2024. The Late Breaking Abstract entitled "Interim Clinical Data Summary: A Phase 1b/2a Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramus
HAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will participate in the Oculopharyngeal Muscular Dystrophy (OPMD) Awareness Day Webinar organized by the OPMD Association, on Monday, September 23, 2024 at 12 PM EST. The event aims to raise awareness of OPMD, a rare, genetic, adult-onset, progressive myopathy with symptom onset beginning between 40-50 years of age. "I am honored to part
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study- -Critically, for three of the four food types evaluated during the radiographic swallowing study assessments for Subject 1, the post-dose average Total Pharyngeal Residue values were lower at the 180-day post-dose assessments than at any point during the 9-month pre-dose observation period compr
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00
Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00
Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00
Guggenheim initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $17.00
Leerink Partners initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $13.00
Piper Sandler initiated coverage of Benitec Biopharma with a rating of Overweight and set a new price target of $30.00
HC Wainwright & Co. initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $10.00